Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
ConditionHidradenitis Suppurativa
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-59
SponsorInstitut Pasteur
About this trial
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
Eligibility criteria
Qualifiers
Adults < 60 years old
Recurrent inflammation occurring more than 2 times in the past 6 months in the inverse regions of the body, presenting with nodules, sinus-tracts and/or scarring.
Signs: Involvement of axilla, genitofemoral area, perineum, gluteal area (and infra-mammary areafor women). Presence of nodules (inflamed or noninflamed), sinus tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like, red, hypertrophic or linear)
Active HS with i) ≥ 1 year of evolution and ii) ≥ 4 flares during the previous year
Disqualifiers
None
Trial design
Treatments tested in this trial
- ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy
- Lymecyclin and corresponding placebos of the experimental arm
Treatment groups
92 Participants
are divided into 2 treatment groupsSponsors and collaborators
Institut Pasteur
Lead sponsor
Centre Hospitalier Universitaire de Caen
Collaborator
Hôpital Necker-Enfants Malades
Collaborator
Ministry of Health, France
Collaborator
Assistance Publique Hopitaux De Marseille
Collaborator
Source ClinicalTrials.gov